Across 98 European nephrology Phase 2 & 3 CTIS trials, 37 trials used at least one CTIS-listed CRO or outsourced support provider, equal to 37.8% of the cohort. IQVIA / Quintiles was the most active provider, appearing in 14 CRO-supported trials, followed by ICON / PRA in 9 and Labcorp / Fortrea in 8. CRO demand was strongest in operationally broader trials: 19 of 27 trials with 5+ countries used CRO support, while IgA nephropathy / IgA vasculitis had the clearest indication-level signal at 9 of 13 trials.
Among the 37 CRO-supported trials, IQVIA / Quintiles appeared in 14 trials, equal to 37.8% of CRO-supported records. ICON / PRA appeared in 9 of 37 trials, Labcorp / Fortrea in 8 of 37, and Parexel, Syneos Health and Suvoda each appeared in 7 of 37.
The active provider market is concentrated around global clinical operations, laboratory and eClinical infrastructure. IQVIA / Quintiles, ICON / PRA, Labcorp / Fortrea, Parexel and Syneos are the clearest broad-service CRO signals, while Suvoda and Medidata indicate frequent outsourcing of digital trial infrastructure rather than full-service trial delivery.
CRO support appeared in 34 of 52 industry-sponsored trials, equal to 65.4%, but only 3 of 46 academic, hospital or other non-industry-sponsored trials, equal to 6.5%. By phase, CRO use was 20 of 50 Phase 3 trials and 16 of 45 Phase 2 trials.
| Segment | CRO-supported / total | Share |
|---|---|---|
| Industry sponsor | 34 / 52 | 65.4% |
| Academic / hospital / other sponsor | 3 / 46 | 6.5% |
| Phase 3 | 20 / 50 | 40.0% |
| Phase 2 | 16 / 45 | 35.6% |
The strongest predictor of CRO use is sponsor model. Industry sponsors are roughly 10 times more likely than academic or hospital sponsors to list CRO support, which means CRO demand is concentrated where cross-border execution, vendor coordination and regulatory operating scale are commercially managed.
Trials involving 5 or more countries had the highest CRO-use rate: 19 of 27 trials, equal to 70.4%. Site count was also strongly associated with outsourcing: 19 of 34 trials with 16 or more sites used CRO support. Participant count was less predictive, with the highest rate seen in the 50–199 participant band at 16 of 36 trials.
In nephrology Phase 2 & 3 trials, CRO demand is more clearly tied to geographic and site-management complexity than to participant volume alone. This is especially relevant for CTIS submissions because multi-country trials require coordinated EU-level submission strategy plus country-level Part II/site readiness execution.
IgA nephropathy / IgA vasculitis had CRO support in 9 of 13 trials, equal to 69.2%, while lupus nephritis had CRO support in 4 of 6 trials, equal to 66.7%. Chronic kidney disease / proteinuria had the largest disease volume, with 12 CRO-supported trials among 36 total trials.
| Disease category | CRO-supported / total | Share |
|---|---|---|
| Chronic kidney disease / proteinuria | 12 / 36 | 33.3% |
| IgA nephropathy / IgA vasculitis | 9 / 13 | 69.2% |
| Lupus nephritis | 4 / 6 | 66.7% |
| Rare genetic kidney disease | 4 / 15 | 26.7% |
| Kidney transplant / rejection | 3 / 15 | 20.0% |
| ESKD / dialysis / kidney failure | 2 / 13 | 15.4% |